


Clinical Guide to Probiotic Products

Available in Canada: 17th Edition



Dosage Formats | Applications | Clinical Evidence to date

Table of Contents

Author

Dragana Skokovic-Sunjic

BScPhm RPh NCMP

Reviewers

Dr Vivien Brown

MDCM CCFP FCFP NCMP

Dr Elsa Dinsdale

MD MSc

Jaimie Hemsworth Hummelen

RD MSc PhD

Iris Krawchenko

BScPhm RPh ACPR

Dr John Marshall

MD MSc FRCPC AGAF

Dr Tom Smiley

BScPhm PharmD

Editor

Rebecca L. Johnson

PhD candidate

Page Number	Content
2	Acronyms for Potential Applications of Probiotics in the Adult and Pediatric Population
3	About this Guide
4	Review Process
5	Inclusion Criteria
6	Level of Recommendation and Disclaimer
7	Probiotic Products for Digestive and Liver Health in Adult Population
10	Probiotic Products for General Health in Adult Population
11	Probiotic Products for Pediatric Population
13	Probiotic Products for Maternal and Vaginal Health
14	Functional Foods with Added Probiotics
15	References
22	Alliance for Education on Probiotics

Acronyms:

AAD	Antibiotic associated diarrhea - Prevention	ID	Infectious diarrhea
BV	Bacterial vaginosis	LDL-C	Reduces LDL and total cholesterol
C	Constipation	LH	Liver Health (NASH/NAFLD/MHE; as adjunct to standard therapy; see studies for specific population)
CDAD	Clostridium difficile associated diarrhea - Prevention	M/A	Mood and Affect (symptoms related to stress/anxiety; not a substitute for standard treatment)
CE/AD	Childhood eczema/ Atopic dermatitis	Mastitis	Mastitis in breastfeeding mothers (treatment and prevention)
CID	Common infectious disease - community acquired	NEC*	Necrotizing Enterocolitis (newborn) *as per hospital protocol, not for self-administration
CMPA	Cow Milk Protein Allergy (<i>including Colic due to CMPA</i>)	NI	Nosocomial infections prevention - hospital acquired
Colic	Colic	OH	Oral health (<i>reductions of tonsillitis, laryngitis, and dental caries</i>)
FAP	Functional abdominal pain	Regurg/ GI Mot	Reduces regurgitation/ Improves gastrointestinal motility
HP	Helicobacter pylori - Adjunct to standard eradication therapy	TD	Traveler's diarrhea prevention
IBD-P	Inflammatory bowel disease - Pouchitis	VC	Vulvovaginal candidiasis
IBD-UC	IBD - Ulcerative colitis - Adjunct to standard therapy	WM	Weight Management (<i>aids in reduction of body weight, body fat mass, and waist circumference</i>)
IBS	Irritable bowel syndrome		

The Clinical Guide to Probiotic Products Available in Canada

This Guide is a practice tool to assist with clinical decision-making for appropriate probiotic therapy for your patients.

It is designed to translate scientific evidence available for probiotic products to practical, clinically relevant information. It is intended to be used as a clinical decision-making tool, enabling clinicians to easily select the appropriate product, dose, and formulation for a specific indication.

Our aim is to ensure that the appropriate product/strain is selected for the desired outcome. This Clinical Guide is not meant to be interpreted as a systematic review, or a "clinical practice guideline," nor is it an endorsement for companies to market health claims.

Currently, the body of evidence for probiotic interventions is growing along with popular demand for these products. There is evidence to support the use of probiotic products for a variety of indications beyond gut health, however, applications and results are strain-specific.

Due to frequent changes in the commercial availability of probiotic strains, new published evidence, and growing research, an annual review and update of this Clinical Guide have been conducted since 2008. A general lack of adverse effects attributable to probiotics supports the widespread use of these products, but an ongoing investigation is recommended.

How is the Guide Reviewed?

A systematic literature review using pre-defined inclusion criteria was undertaken to identify studies of defined clinical outcomes for specific probiotic strain(s). Commercially available products containing said strain(s) were identified, and the levels of evidence were used to rate the strength of the expected benefit. This information was compiled into a chart format. Data was assessed by a group of independent expert reviewers.

In the case of probiotics, the clinical evidence must be linked to specific formulations as defined by genus, species, alphanumeric designation or strain, number of live bacteria present, the blend of probiotic strains present, and finally, non-active ingredients present.

Every attempt was made to include the published clinical data for the available probiotic formulations.

To avoid selection bias toward any specific formulation, we have conducted a literature search of two databases (PubMed, EMBASE) and contacted our independent experts to identify any published or unpublished studies.

Why are only a Limited Number of Products Included?

All of the inclusion criteria listed must be satisfied for a product to be listed in the Guide:

1. Commercially available in Canada as a supplement or probiotic-containing food.
2. Generally Recognized as Safe status (FDA) and/or Natural Product Number (Health Canada) for probiotic strain(s) used in the products.
3. Favourable published clinical evidence for the particular strain(s) present in each product.
4. For products containing multiple strains, evidence must be for the specified combination and NOT extrapolated from the evidence for the separate probiotic strains.

Note: Some products are excluded from the current edition due to changes in the strains used.

Clinical Pearl: Indications for use are based on specific strains or combinations studied together.

Caution: Extrapolation of current data and recommendations to be applied for different combinations of probiotic strains is not permitted.

Level of Recommendation:

Level I	Evidence obtained from at least one appropriately designed trial (e.g. randomization, blinding, appropriate population comparisons) with a power calculation for the outcome(s) of interest. The expert review board reserves the right to make the final decision for the level of recommendation. (HIGHEST LEVEL)
Level II	Evidence obtained from well-designed controlled trials without randomization. Evidence obtained from randomized trials not satisfying all criteria listed in Level I. Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group. Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be regarded as this type of evidence.
Level III	Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

Readers are strongly encouraged to review the evidence listed for each product for themselves.

Please refer to individual publications for specifics of patient populations studied (e.g. age, gender, comorbidities) and details of clinical effect (statistical significance, size of treatment effect, precision of the confidence intervals).

Disclaimer

The statements made regarding products listed here have not been evaluated by the Food and Drug Administration or Health Canada (unless otherwise indicated). These products are not intended to diagnose, treat, cure, or prevent any disease. Products, services, information, and other content provided in this Guide, including information that may be provided in this Guide directly or by linking to third-party affiliates are provided for informational purposes only. Please consult with a physician or another healthcare professional regarding any medical or health-related questions. Manufacturer indications for use can be found on product labels. This chart is reflective of published evidence available to date. It does not represent an endorsement of any specific product. Work on this Guide is done independently and without financial conflict. In order to minimize bias, publishing and distribution efforts are coordinated via Alliance for Education on Probiotics (AEP probio). We are grateful for the unrestricted publishing grant AEP probio is providing for continuous efforts to translate science into a clinically applicable form.

Please forward any questions or comments to DSunjic@bhsoftinc.com

Probiotic Products for Digestive and Liver Health in Adult Population:

Brand Name	Probiotic Strain(s)	Dosage Form	CFU/Dose	No. of Doses/Day	C	HP	CDAD	IBS	ID	AAD	IBD-P	TD
Align®	<i>B. longum</i> 35624	Capsule	1B/capsule	1 capsule				I (1-4)				
Align® Chewables		Tablet	1B/tablet	1 tablet				I (1-4)				
Align® Probiotic Gummies	<i>Bacillus coagulans</i> MTCC 5856	Chewable gummy	1B/gummy	2 gummies				II (5)				
Bio-K+® Antibio Pro Shelf stable and refrigerated options available	<i>L. acidophilus</i> CL1285 <i>L. casei</i> LBC80R <i>L. rhamnosus</i> CLR2	Capsule	50B/capsule	1-2 capsules				I (7-11)			I (6-8)	
Bio-K+® Drinkable Probiotics		Ferm. milk Ig. Ferm. vegan Ig.	50B/bottle 50B/bottle	1 bottle 1 bottle				I (7-11)			I (6-8)	
Bio-K+® IBS Pro		Capsule	50B/capsule	2 capsules				I (19)				
BioGaia® Protectis® Baby Drops	<i>L. reuteri</i> DSM 17938	Drops	100M/5 drops	5 drops	I (18)	I (14-17)			II (12)	II (13)		
BioGaia® Protectis® Chewable Tablets		Chewable tablet	100M/tablet	1 tablet	I (18)	I (14-17)			II (12)	II (13)		
BioGaia® Protectis® Drops with Vitamin D		Drops	100M/5 drops	5 drops	I (18)	I (14-17)			II (12)	II (13)		
BioGaia® Junior Tablets with Vitamin D		Chewable tablet	100M/tablet	1 tablet	I (18)	I (14-17)			II (12)	II (13)		
Biomed Bacillus Coagulans	<i>Bacillus coagulans</i> MTCC 5856	Capsule	1B/capsule	2 capsules				II (5)				
Culturelle® Digestive Health Daily Probiotic Capsules	<i>L. rhamnosus</i> GG	Capsule	10B/capsule	1 capsule		I (24)	III (25-27)			I (23)	II (28)	II (29-30)

- Product requires refrigeration

- Approved by Health Canada for listed indication; applicable to supplements

- Gluten Free

Probiotic Products for Digestive and Liver Health in Adult Population:

Brand Name	Probiotic Strain(s)	Dosage Form	CFU/Dose	No. of Doses/Day	IBD UC	HP	CDAD	IBS	AAD	TD
Florastor® Daily 🍃	<i>Saccharomyces boulardii</i> lyo CNCM I-745	Capsule	2.5B/capsule	2-4 capsules	III (37,41-44)	I (38-40)	I (9-10,32-33,45)		I (31-32)	I (34-36)
Florastor® Extra Strength 🍃		Sachet	5B/sachet	1-2 sachets	III (37,41-44)	I (38-40)	I (9-10,32-33,45)		I (31-32)	I (34-36)
Florastor® Immunity 🍃 (with vit C 60mg, vit D 400IU, zinc gluconate 10mg)		Capsule	2.5B/capsule	2-4 capsules	III (37,41-44)	I (38-40)	I (9-10,32-33,45)		I (31-32)	I (34-36)
HMF	Forte 🍃	<i>L. acidophilus</i> CUL-60 <i>L. acidophilus</i> CUL-21 <i>B. animalis</i> subsp. <i>lactis</i> CUL-34 <i>B. bifidum</i> CUL-20	Capsule	10B/capsule	2-3 capsules		II (46)	II (47)		
	IBS Relief 🍃		Capsule	25B/capsule	1 capsule		II (46)	II (47)		
	Intensive 🍃		Capsule	25B/capsule	1 capsule		II (46)	II (47)		
	Intensive 50 🍃		Capsule	50B/capsule	1 capsule		II (46)	II (47)		
	Intensive Powder ❄️ 🍃		Powder	25B/1 scoop (1 gram)	1 scoop		II (46)	II (47)		
	Super Powder ❄️ 🍃		Powder	10B/1 scoop (1 gram)	2-3 scoops		II (46)	II (47)		
Jamieson™ Probiotic 10 Billion Active Cells* Daily Maintenance	<i>Lactococcus lactis</i> (UALI-08) <i>L. gasseri</i> (UALg-05) <i>L. rhamnosus</i> (UALr-06) <i>B. animalis</i> subsp. <i>lactis</i> (UABla-12) <i>B. breve</i> (UABb-11) <i>L. paracasei</i> (UALpc-04) <i>L. rhamnosus</i> (UALr-18) <i>L. acidophilus</i> (DDS@-1) <i>L. plantarum</i> (UALp-05) <i>B. longum</i> subsp. <i>longum</i> (UABI-14) <i>B. bifidum</i> (UABB-10) <i>L. casei</i> (UALc-03) <i>L. reuteri</i> (UALre-16) <i>B. longum</i> subsp. <i>infantis</i> (UABI-13)	Capsule	10B/capsule	3 capsules	II (60)					
Mutaflor® ❄️	<i>Escherichia coli</i> Nissle 1917	Capsule	2.5-25B/capsule	1-2 capsules	I (49-52)					

❄️ - Product requires refrigeration

✳️ - Approved by Health Canada for listed indication; applicable to supplements

🍃 - Gluten Free

Probiotic Products for Digestive and Liver Health in Adult Population:

Brand Name	Probiotic Strain(s)	Dosage Form	CFU/Dose	No. of Doses/Day	C	IBD-UC	CDAD	IBS	AAD	IBD-P	LH
Purica Probiotic Intensive GI	<i>L. plantarum</i> CECT7484/KABP022® <i>L. plantarum</i> CECT7485/KABP023® <i>P. acidilactici</i> CECT7483/KABP021®	Capsule	3B/capsule	1 capsule				I (64-65)			
Ultra Probiotic Complex by GNC	<i>L. acidophilus</i> CUL-60 <i>L. acidophilus</i> CUL-21 <i>B. bifidum</i> CUL-20 <i>B. lactis</i> CUL-34	Packet Capsule	25B/packet 25B/ 50B/ 75B per capsule	1-2 packets 1-2 capsules			II (46)	II (47)			
UltraFlora® Balance	<i>L. acidophilus</i> NCFM® <i>B. lactis</i> Bi-07®	Capsule	15B/capsule	2 capsules				II (75)			
UltraFlora® Intensive Care	<i>L. plantarum</i> 299v	Capsule	10B/capsule	2 capsules			III (67,71)	I (68-70)	III (66)		
UltraFlora® Restore	<i>B. lactis</i> Bi-07® <i>L. acidophilus</i> NCFM® <i>B. lactis</i> Bi-04 <i>L. paracasei</i> Lpc-37	Capsule	20B/capsule	1 capsule				I (72-73)			
Visbiome®	<i>L. acidophilus</i> DSM24735/SD5212 <i>L. paracasei</i> DSM24733/SD5218 <i>L. delbrueckii</i> subsp. <i>bulgaricus</i> DSM24734/SD5210 <i>L. plantarum</i> DSM24730/SD5209 <i>B. longum</i> DSM24736/SD5220 <i>B. infantis</i> DSM24737/SD5219 <i>B. breve</i> DSM24732/SD5206 <i>S. thermophilus</i> DSM24731/SD5207	Sachet	450B/sachet	1-4 sachets	II (78,89)	I (79-81)			I (80,82-84)	I (85-88,90-91)	

- Product requires refrigeration

- Approved by Health Canada for listed indication; applicable to supplements

- Gluten Free

Probiotic Products for General Health in Adult Population:

Brand Name	Probiotic Strain(s)	Dosage Form	CFU/Dose	No. of Doses/Day	LDL-C	WM	OH	CID	M/A
BioGaia® ProDentis™	<i>L. reuteri</i> ATCC PTA 5289 <i>L. reuteri</i> DSM 17938	Lozenge	200M/lozenge	1 lozenge			I (55-59)		
Calm Biotic®	<i>B. longum</i> R0175 <i>L. helveticus</i> R0052	Capsule	3B/capsule	1 capsule					II (20-22)
CulturedCare® Probiotic Gum with BLIS K12®	<i>Streptococcus salivarius</i> K12	Lozenge	0.5B/lozenge	2-10 lozenges			II (53-54)		
HMF Metabolic	<i>L. acidophilus</i> CUL-60 <i>L. acidophilus</i> CUL-21 <i>L. plantarum</i> CUL-66 <i>B. animalis</i> subsp. <i>lactis</i> CUL-34 <i>B. bifidum</i> CUL-20	Capsule	50B/capsule	1 capsule			II (48)		
ProbioMAX® Women	<i>B. longum</i> R0175 <i>L. helveticus</i> R0052	Capsule	1.5B/capsule	2 capsules					II (20-22)
Purica Probiotic Cardio	<i>L. plantarum</i> CECT7527/KABP011® <i>L. plantarum</i> CECT7528/KABP012® <i>L. plantarum</i> CECT7529/KABP013®	Capsule	1B/capsule	1 capsule	II (61-63)				
UltraFlora® Control	<i>B. animalis</i> ssp. <i>lactis</i> 420 (B420™)	Capsule	10B/capsule	1 capsule			I (74)		
UltraFlora® Cold Support	<i>L. plantarum</i> HEAL9 <i>L. paracasei</i> 8700:2	Capsule	1B/capsule	1 capsule				I (76-77)	

- Product requires refrigeration

- Approved by Health Canada for listed indication; applicable to supplements

- Gluten Free

Probiotic Products for Pediatric Population:

Brand Name	Probiotic Strain(s)	Dosage Form	CFU/Dose	No. of Doses/Day	AAD	C	CE/AD	CD	Colic	FAP	IBS	ID	LH	NEC*	NI	OH	Regurg/GI Mot
Baby Ddrops® Probiotic	<i>B. longum</i> CECT7894/ KABP042® <i>P. pentosaceus</i> CECT8330/KABP041®	Drops	1B/5 drops	5 drops					I *(141-142)								
BioGaia® Protectis® Baby Drops	<i>L. reuteri</i> DSM 17938	Drops	100M/5 drops	5 drops	I (104)	I *(105-106)	II (111-112)	I (109-110)	I *(95-98,113-114)	I (107-108)	I (107-108)	I *(99-103)		I (115-117)			I *(92-94)
BioGaia® Protectis® Chewable Tablets		Chewable tablet	100M/tablet	1tablet	I (104)	I *(105-106)	II (111-112)	I (109-110)	I *(95-98)	I (107-108)	I (107-108)	I *(99-103)					I (92-94)
BioGaia® Protectis® Drops with Vitamin D		Drops	100M/5 drops	5 drops	I (104)	I *(105-106)	II (111-112)	I (109-110)	I *(95-98,113-114)	I (107-108)	I (107-108)	I *(99-103)					I *(92-94)
BioGaia® Junior Tablets with Vitamin D		Chewable tablet	100M/tablet	1tablet	I (104)	I *(105-106)	II (111-112)	I (109-110)	I *(95-98)	I (107-108)	I (107-108)	I *(99-103)					I (92-94)
BioGaia® ProDentis™ Kids	<i>L. reuteri</i> ATCC PTA 5289 <i>L. reuteri</i> DSM 17938	Lozenge	200M/lozenge	1lozenge												I *(55-59,153-155)	
CulturedCare® Probiotic Gum with BLIS K12®	<i>Streptococcus salivarius</i> K12	Lozenge	1B/lozenge	1-5 lozenges												I *(53-54)	
Culturelle® Baby Calm + Colic Probiotic Drops	<i>B. longum</i> CECT7894/ KABP042® <i>P. pentosaceus</i> CECT8330/KABP041®	Drops	1B/5 drops	5 drops					I *(141-142)								
Culturelle® Immune Support + Vitamin D		Drops	1B/5 drops	5 drops					I *(141-142)								
Culturelle® Kids Daily Probiotic Chewables		Chewable tablet	5B/tablet	2-4 tablets	I (124-125)		I (129-135,140)	I (139)		I (126-127)	I (126-127)	I (118-123,138)	I (136-137)		I (128)		
Culturelle® Kids Daily Probiotic Packets		Powder	5B/packet	2-4 packets	I (124-125)		I (129-135,140)	I (139)		I (126-127)	I (126-127)	I (118-123,138)	I (136-137)		I (128)		
Culturelle® Kids Immune Defense Probiotic	<i>L. rhamnosus</i> GG	Chewable tablet	5B/tablet	2-4 tablets	I (124-125)		I (129-135,140)	I (139)		I (126-127)	I (126-127)	I (118-123,138)	I (136-137)		I (128)		

* - Approved by Health Canada for listed indication; applicable to supplements

GF - Gluten Free

Probiotic Products for Pediatric Population:

Brand Name	Probiotic Strain(s)	Dosage Form	CFU/Dose	No. of Doses/ Day	AAD	CDAD	CE/AD	CID	Colic	HP	IBD-UC	IBS	ID	LH
Florastor® Kids	<i>Saccharomyces boulardii</i> lyo CNCM I-745	Sachet	2.5B/sachet	2-4 sachets	I (146)	III (147)			I (39,148)				I * (143-145)	
HMF Baby Drops	<i>B. longum</i> CECT7894/KABP042® <i>P. pentosaceus</i> CECT8330/ KABP041®	Drops	1B/5 drops	5 drops				I (141-142)						
HMF Fit for School [50mg vitamin C, 1000IU vitamin D]	<i>L. acidophilus</i> CUL-60 <i>L. acidophilus</i> CUL-21 <i>B. animalis</i> subsp. <i>lactis</i> CUL-34 <i>B. bifidum</i> CUL-20	Chewable tablet Powder	12.5B/tablet 12.5B/scoop	1tablet 1scoop				I (149)						
MetaKids™ Baby Probiotic	<i>L. rhamnosus</i> GG <i>B. lactis</i> BB-12	Drops	1B/6 drops	6 drops			II (151)	II (150)						
MetaKids™ Probiotic	<i>L. acidophilus</i> NCFM® <i>B. animalis</i> subsp <i>lactis</i> Bi-07®	Chewable tablet	5B/tablet	2 tablets				I (152)						
Orange Naturals Baby Probiotics +D3 Drops (400IU)	<i>L. rhamnosus</i> GG <i>B. lactis</i> BB12	Drops	2B/5 drops	5 drops			II (151)	II (150)						
Orange Naturals Probiotics Kids Chewable + Vitamin A,C,D3	<i>L. acidophilus</i> NCFM <i>B. animalis</i> subsp <i>lactis</i> Bi-07	Chewable tablet	5B/tablet	1 tablet				I (152)						
ProZema®	<i>B. lactis</i> BPL1 CECT 8145 <i>B. longum</i> E1 CECT 7347 <i>L. casei</i> BPL4 CECT 9104	Stick	1.55B/stick	1 stick			I * (156-157)							
Probiotic Baby	<i>B. lactis</i> BB-12	Drops	1B/6 drops	6 drops				I (158)	I (159)					
Visbiome®	This combination of strains is known as De Simone Formulation and is the same one listed in references that cite VSL#3 as treatment regimen	<i>L. acidophilus</i> DSM24735/SD5212 <i>L. paracasei</i> DSM24733/SD5218 <i>L. delbrueckii</i> subsp. <i>bulgaricus</i> DSM24734/SD5210 <i>L. plantarum</i> DSM24730/SD5209 <i>B. longum</i> DSM24736/SD5220 <i>B. infantis</i> DSM24737/SD5219 <i>B. breve</i> DSM24732/SD5206 <i>S. thermophilus</i> DSM24731/SD5207	Sachet	450B/sachet	1-2 sachets						I * (161-162)	I * (163)	I (160)	I (164)

* - Product requires refrigeration

* - Approved by Health Canada for listed indication; applicable to supplements

Gluten Free

Probiotic Products for Maternal and Vaginal Health:

Brand Name	Probiotic Strain(s)	Dosage Form	CFU/Dose	No. of Doses/ Day	BV	VC
Bio-K+® Women's Health 	<i>L. reuteri</i> RC-14 <i>L. rhamnosus</i> GR-1	Oral capsule	1B each/capsule	1-2 capsules	 (165,167-169,171-172)	 (166,169-170)
Probaciac BV®	<i>L. acidophilus</i> A-212 <i>L. rhamnosus</i> A-119 <i>S. thermophilus</i> A-336	Vaginal capsule	8B/capsule	1-2 capsules	 (173)	
Provacare®	<i>L. rhamnosus</i> Lcr35	Vaginal ovule	3.41B/ovule	2 ovules	 (175-177)	 (174)
RepHresh™ Pro-B™ Probiotic 	<i>L. rhamnosus</i> GR-1 <i>L. reuteri</i> RC-14	Oral capsule	0.5B each/capsule	2-4 capsules	 (165,167-169,171-172)	 (166,169-170)
UltraFlora® Women's 	<i>L. reuteri</i> RC-14 <i>L. rhamnosus</i> GR-1	Oral capsule	1B each/capsule	1-2 capsules	 (165,167-169,171-172)	 (166,169-170)

 - Approved by Health Canada for listed indication; applicable to supplements

 - Gluten Free

Functional Foods with Added Probiotics (Adults):

Brand Name	Probiotic Strain(s)	CFU/Dose	No. of Doses/Day	AAD	C	CDAD	CID	IBS	M/A
Activia® ❄	<i>B. (animalis) lactis</i> CNCM I-2494	1B/serving	1-3 servings		I (180)			I (178-179)	
GoodBelly® Probiotic Juice Drinks	<i>L. plantarum</i> 299v	20B/serving (8oz)	1 serving	III (66)		III (67,71)		I (68-70)	
GoodBelly® Probiotic SuperShot Dairy-free drinks ❄		50B/80mL serving	1/3 - 1/2 serving	III (66)		III (67,71)		I (68-70)	
Yakult ❄	<i>L. casei</i> Shirota	8B/bottle (80mL)	1-2 bottles		I (187-188)		I (189-192)		II (193-194)

Functional Foods with Added Probiotics (Children):

Brand Name	Probiotic Strain(s)	CFU/Dose	No. of Doses/Day	AAD	CID	CMPA	ID
Gerber® Baby Cereals	<i>B. lactis</i> BB-12	1B/serving [serving=5 tbls]	1 serving	I (182)	I (158,181)		
Gerber® Toddler Cereals	<i>B. lactis</i> BB-12	1B/serving [serving=5 tbls]	1 serving	I (182)	I (158,181)		
Good Grow® Nutritional Toddler Drink	<i>B. lactis</i> BB-12	1B/200mL serving	1 serving	I (182)	I (158,181)		
Good Start Soothe™ Infant Formula	<i>L. reuteri</i> DSM 17938	1M/gram	Routine feeding if an alternative to breast milk is required				I (99-103)
Good Start® Plus 1 Infant Formula	<i>B. lactis</i> BB-12	1M/gram	Routine feeding if an alternative to breast milk is required		I (158,181)		
Good Start® Plus 2 Infant Formula (6 months+)	<i>B. lactis</i> BB-12	130M/100mL serving	Routine feeding if an alternative to breast milk is required	I (182)	I (158,181)		
Nestlé® Nido® Nutritional Toddler Drink	<i>B. lactis</i> BB-12	1B/225mL serving	1 serving	I (182)	I (158,181)		
Nutramigen® A+® with LGG® Extensively hydrolyzed casein formula (EHCF)	<i>L. rhamnosus</i> GG [Branded LGG]	1.35×10^7 CFU per 100mL serving	EHCF when an alternative to breast milk is required			I (183-186)	

❄ - Product requires refrigeration

References:

- 1 Brenner, DM, and WD Chey. "Bifidobacterium infantis 35624: A Novel Probiotic for the Treatment of IBS." *Reviews in Gastroenterological Disorders* 9.1 (2009): 7-15.
- 2 Quigley, EM, PJ Whorwell, L Altriger, J Morel, L O'Mahony, and F Shanahan. "Probiotic Use Results in Normalization of Bowel Movement Frequency in IBS. Results from a Clinical Trial with the Novel Probiotic Bifidobacterium infantis 35624." *American Journal of Gastroenterology* 100.S9 (2005): S326.
- 3 Whorwell, P., L. Altriger, J. Morel, Y. Bond, D. Charbonneau, L. O'Mahony, B. Kiely, F. Shanahan, and EM Quigley. "Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome." *American Journal of Gastroenterology* 101 (2006): 1581-590.
- 4 O'Mahony, L., J. McCarthy, P. Kelly, G. Hurley, F. Luo, K. Chen, G. C. O'Sullivan, B. Kiely, J. K. Collins, F. Shanahan, and E. M. Quigley. "Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles." *Gastroenterology* 128.3 (2005): 541-51.
- 5 Majed, Muhammed et al. "Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study." *Nutrition journal* vol. 15 21. 27 Feb. 2016, doi:10.1186/s12937-016-0140-6
- 6 Beausoleil, M., N. Fortier, S. Guenette, A. L'Ecuyer, M. Savoie, M. Franco, J. Lachaine, and K. Weiss. "Effect of a Fermented Milk Combining Lactobacillus Acidophilus CL1285 And Lactobacillus Casei In the Prevention of Antibiotic-Associated Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Trial." *Canadian Journal of Gastroenterology* 21.1 (2007): 732-36.
- 7 Gao, X. W., M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller. "Dose-Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients." *American Journal of Gastroenterology* 105.7 (2010): 1636-641.
- 8 Sampalis, J., E. Psaradellis, and E. Rampakakis. "Efficacy of Bio K+ CL1285® in the Reduction of Antibiotic-Associated Diarrhea: A Placebo Controlled Double-Blind Randomized, Multi-Center Study." *Archives of Medical Science: AMS* 6.1 (2010): 56-64.
- 9 Johnston, B. C., S. S.Y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. "Probiotics for the Prevention of Clostridium difficile -Associated Diarrhea: A Systematic Review and Meta-analysis." *Annals of Internal Medicine* 157(2) (2012): 878
- 10 Johnson, S., P. J. Maziaze, L. V. McFarland, W. Trick, C. Donskye, B. Currie, D. E. Low, and E. J.C Goldstein. "Is Primary Prevention of Clostridium difficile Infection Possible with Specific Probiotics?" *International Journal of Infectious Diseases* 6.11 (2012): E786-792.
- 11 McFarland, L.V., N. Ship, J. Auclair and M. Millette. "Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence." *Journal of Hospital Infection* 99.4 (2018):443-452.
- 12 Aiello, R. A., M. Ali, M. Chiarenza, G. Carillo, G. Scandurra, and M. Caruso. "Efficacy and Safety of Lactobacillus Reuteri ATCC 55730 in Preventing Acute Chemotherapy Induced Diarrhea in Colon Cancer Patients Treated with DeGramont or Folfox Schedule." *Annals of Oncology*. S9 ed. Vol. 19. (2008).
- 13 Cimperman, L., G. Bayless, K. Best, A. Diligente, B. Mordarski, M. Oster, M. Smith, F. Vatakis, D. Wiese, A. Steiber, and J. Katz. "A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus Reuteri ATCC 55730 for the Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults." *Journal of Clinical Gastroenterology* 45.9 (2011): 785-89.
- 14 Aihara, M.e., E.c. Nista, G. Vitale, V. Ojetti, V. Cesario, G. Gigante, L. Sparano, M.I. Novi, D. Roccarina, G. Cammarota, G. Gasbarini, and A. Gasbarini. "Pa.29 Impact Of L. Reuteri Supplementation On Anti-H. Pylori Second Line Therapy-Related" *Digestive and Liver Disease* 40 (2008)
- 15 Francavilla, R., E. Lionetti, S. P. Castellaneta, A. M. Magista, G. Maurogianni, N. Bucci, A. De Canio, F. Indrio, L. Cavallo, E. Ierardi, and V. L. Minella. "Inhibition of Helicobacter pylori Infection in Humans by Lactobacillus Reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study." *Helicobacter* 13.2 (2008): 127-34.
- 16 Imase, K., A. Tanaka, K. Tokunaga, H. Sugano, H. Ishida, and S. Takahashi. "Lactobacillus Reuteri Tablets Suppress Helicobacter Pylori Infection—a Double-blind Randomised Placebo-controlled Cross-over Clinical Study." *Journal of the Japanese Association for Infectious Diseases* 81.4 (2007): 387-93.
- 17 Saggioro, A., M. Caroli, M. Pasini, F. Bartoluzzi, L. Girardi, and G. Piloni. "Helicobacter Pylori Eradication with Lactobacillus Reuteri: A Double Blind Placebo-controlled Study." *Dig Liver Dis* 37 Suppl 1 (2005): S88.
- 18 Ojetti, V., G. Ianino, A. Tortora, G. D'Angelo, T. A. Di Renzo, S. Bibbo, A. Migneco, and A. Gasbarini. "The Effect of Lactobacillus Reuteri Supplementation in Adults with Chronic Functional Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial." *Journal of Gastrointestinal and Liver Diseases* 23.4 (2014): 387-91.
- 19 Preston, K., R. Kruisman, J. Hattner, D. de Montigny, M. Stewart, and S. Gaddam. "Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study." *Beneficial Microbes* 9.5 (2018): 697-706.
- 20 Huang R., H. Ning, L. Yang, C. Jia, F. Yang, G. Xu, and H. Tan. "Efficacy of Probiotics on Anxiety: A Meta-analysis of Randomized Controlled Trials." *Neuropsychiatry* 7.6 (2017): 862-71.
- 21 Messaoudi, M., R. Lalonde, N. Vioille, H. Javelot, D. Desor, A. Nejdi, J. Bisson, C. Rougeot, M. Pichelin, M. Cazaubiel, and J. Cazaubiel. "Assessment of Psychotropic-like Properties of a Probiotic Formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in Rats and Human Subjects." *British Journal of Nutrition* 105.05 (2010): 755-64.
- 22 Messaoudi, M., N. Vioille, J. Bisson, D. Desor, H. Javelot, and C. Rougeot. "Beneficial Psychological Effects of a Probiotic Formulation (Lactobacillus helveticus R0052 And Bifidobacterium longum R0175) in Healthy Human Volunteers." *Gut Microbes* 2.4 (2011): 256-61.
- 23 Kale-Pradhan, P. B., H. K. Jassal, and S. M. Wilhelm. "Role of Lactobacillus in the Prevention of Antibiotic-Associated Diarrhea: A Meta-analysis." *Pharmacotherapy* 30.2 (2010): 119-26.
- 24 Armuzzi, A., F. Cremonini, F. Bartolozzi, F. Canducci, M. Candelli, V. Ojetti, G. Cammarota, M. Antl, A. De Lorenzo, P. Pola, G. Gasbarini, and A. Gasbarini. "The Effect of Oral Administration of Lactobacillus GG on Antibiotic-associated Gastrointestinal Side-effects during Helicobacter Pylori Eradication Therapy." *Alimentary Pharmacology and Therapeutics* 15.2 (2001): 163-69.
- 25 Gorbach, S. L., Chang, T. W., & Goldin, B. "Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG." *Lancet* 2, 159 (1987).
- 26 Bennett, RG, Gorbach SL et al. "Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG" *Nutr Today Suppl Vol 31 No 6 Nov/Dec 1996*
- 27 Morrow, L. E., Kollef, M. H., & Casale, T. B. "Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial." *American journal of respiratory and critical care medicine* 182, 1058-1064 (2010).
- 28 Goseleini MP, Schouten WR et al. "Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG" *Dis Colon Rectum* 2004; 47: 876-84
- 29 Oksanen, P.J., et al. "Prevention of travellers' diarrhoea by Lactobacillus GG." *Annals of medicine*, 1990, 22(1): p. 53-56.
- 30 Hilton, E., et al. "Efficacy of Lactobacillus GG as a diarrheal preventive in travelers." *Journal of travel medicine*, 1997, 4(1): p. 41-43.
- 31 Can, M., B. A. Besirbeglioglu, I. Y. Avci, C. M. Beker, and A. Pahsa. "Prophylactic Saccharomyces boulardii in the Prevention of Antibiotic-associated Diarrhea: A Prospective Study." *Medical Science Monitor* 12.4 (2006): PT19-22.
- 32 Surawicz, C. M., L. V. McFarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. Bowen, D. Borjal, and G. W. Elmer. "The Search for a Better Treatment for Recurrent Clostridium difficile Disease: Use of high-dose Vancomycin Combined With Saccharomyces boulardii." *Clinical Infectious Diseases* 31.4 (2000): 1012-017.
- 33 McFarland, L. V., C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer, K. A. Moyer, S. A. Melcher, K. E. Bowen, J. L. Cox, Z. Noorani, G. Harrington, M. Rubin, and D. Greenwald. "A Randomized Placebo-controlled Trial of Saccharomyces boulardii in Combination with Standard Antibiotics for Clostridium difficile Disease." *JAMA: The Journal of the American Medical Association* 271.24 (1994): 1913-918.
- 34 Kollaritsch, H., P. Kremsner, G. Wiedermann, and O. Schneide. "Prevention of traveller's diarrhea: comparison of different non-antibiotic preparations." *Travel Med Int* 11 (1989): 9-17.
- 35 Kollaritsch, H., H. Holst, P. Grobara, and G. Wiedermann. "Prophylaxis of traveller's diarrhoea with Saccharomyces boulardii." *Fortschr Med* 111 (1993): 152-156. (Article in German)
- 36 McFarland, L. V. "Meta-analysis of probiotics for the prevention of traveler's diarrhea." *Travel medicine and infectious disease* 5.2 (2007): 97-105.
- 37 Guslandi, M., G. Mezzi, M. Sorghi, and P.A. Testoni. "Saccharomyces boulardii in maintenance treatment of Crohn's disease." *Digestive diseases and sciences* 45.7 (2000): 1462-1464.
- 38 Song, M. J., D. Park, J. H. Park, H. J. Kim, Y. K. Cho, C. I. Sohn, W. K. Jeon, and B. I. Kim. "The Effect of Probiotics and Mucoprotective Agents on PPI-Based Triple Therapy for Eradication of Helicobacter pylori." *Helicobacter* 15.3 (2010): 206-213.
- 39 Szajewska, H., A. Horvath, and A. Piwowarczyk. "Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment." *Alimentary pharmacology & therapeutics* 32.9 (2010): 1069-1079.
- 40 Cindoruk, M., G. Erkan, T. Karakan, A. Dursun, and S. Unal. "Efficacy and Safety of Saccharomyces boulardii in Helicobacter 12.4 (2007): 309-316.
- 41 Guslandi, M., Giollo, P., and Testoni, P. " (2003). A pilot trial of Saccharomyces boulardii in ulcerative colitis." *European Journal Of Gastroenterology And Hepatology* 15, 697-698.
- 42 Sivananthan, K., and Petersen, A. " (2018). Review of Saccharomyces boulardii as a treatment option in IBD." *Immunopharmacology And Immunotoxicology* 40, 465-475.
- 43 Tang, H., Wu, H., Mao, J., Zhu, L., Li, N., and Wang, Y. " (2014). Clinical study on saccharomyces boulardii in the treatment of patients with mild to moderate ulcerative colitis." *11th IEEE International Conference On Control And Automation (ICCA)*.
- 44 Zhou, W. " (2017). Saccharomyces boulardii powder combined with mesalazine for treatment of active ulcerative colitis: Curative effect and impact on fecal calprotectin and serum inflammatory factors." *World Chinese Journal Of Digestology* 25, 2065.
- 45 Flatley EA, Wilde AM, Nailor MD. "Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection." *J Gastrointest Liver Dis*. 2015;24(1):21-24

- 46** Plummer, S., M.A. Weaver, J.C. Harris, P. Dee, and J. Hunter. "Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhea." *International Microbiology* 7.1 (2010): 59–62.
- 47** Williams, E. A., J. Stimpson, D. Wang, S. Plummer, I. Garaiova, M.E. Barker, and B.M. Corfe. "Clinical trial: a multistain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study." *Alimentary pharmacology & therapeutics* 29.1 (2009): 97–103.
- 48** Michael, D.R., Jack, A.A., Masetti, C. et al. "A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being." *Sci Rep* 10, 4183 (2020). <https://doi.org/10.1038/s41598-020-60917>
- 49** Flöch, Martin H. "Probiotic therapy for ulcerative colitis." *Journal of clinical gastroenterology* 44.4 (2010): 237–238.
- 50** Henker, J., S. Müller, M.W Laas, A. Schreiner, and J. Schulze. "Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study." *Zeitschrift fuer Gastroenterologie* 46.09 (2008): 874–875.
- 51** Kruis, W., E. Schütz, P. Frix, B. Fixa, J. Judmaier, and M. Stolte. "Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis." *Alimentary pharmacology & therapeutics* 11.5 (1997): 853–858.
- 52** Kruis, W., P. Frix, J. Pokrotnieks, M. Lukáš, B. Fixa, M. Kaščák, M.A. Kamm, J. Weismüller, C. Beglinger, M. Stolte, and C. Wolff. "Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine." *Gut* 53.11 (2004): 1617–1623.
- 53** Burton, J. P., C.N. Chilcott, C. J. Moore, G. Speiser, and J. R. Tagg. "A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters." *Journal of applied microbiology* 100.4 (2006): 754–764.
- 54** Di Piero, F.G., G. Donato, F. Fornia, T. Adami, D. Careddu, C. Cassandro, and R. Albera. "Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media." *International journal of general medicine* 5 (2012): 991.
- 55** Schlagenhauf, U., Jakob L. et al. "Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT." *J Clin Periodontol.* 2016 Nov;43(11):948-954
- 56** Teughels W, Durukan A, et al. "Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study." *J Clin Periodontol* 2013; 40: 1025–1035
- 57** Galofré M, Palao D, Vicario M, Nart J, Violant D. "Clinical and microbiological evaluation of the effect of Lactobacillus reuteri in the treatment of mucositis and peri-implantitis: A triple-blind randomized clinical trial." *J Periodontal Res.* 2018 Jun;53(3):378-390.
- 58** Kraft-Bodl E, Jørgensen M, Keller MK. "Effect of Probiotic Bacteria on Oral Candida in Frail Elderly." *J Dent Res.* 2015 Sep;94(9 Suppl):181S-6S
- 59** Tekce M, Ince G, Gursoy H, et al. "Clinical and microbiological effects of probiotic lozenges in the treatment of chronic periodontitis: a 1-year follow-up study." *J Clin Periodontol* 2015; 42: 363–372
- 60** Agraria, Liana M et al. "Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study." *Clinical nutrition ESPEN* vol. 51 (2022): 83–91. doi:10.1016/j.clnesp.2022.08.020
- 61** Fuentes, Mari C et al. "Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults." *The British journal of nutrition* vol. 109,10 (2013): 1866–72.
- 62** Kerlikowsky F, Greupner T, Müller M, Mazo JE, Müller HJ, Hahn A. Probiotic formulation influences blood cholesterol levels: a randomized, controlled trial during the covid19 pandemic. *Clin Nutr ESPEN*. 2021
- 63** Fuentes, Mari C, et al. "A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol." *Mediterranean Journal of Nutrition and Metabolism* 9.2 (2016): 125–135.
- 64** Lorenzen-Zúñiga, Vicente et al. "I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life." *World journal of gastroenterology* vol. 20,26 (2014): 8709–16.
- 65** Barraza-Ortiz, Diego A et al. "Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study." *Digestive diseases (Basel, Switzerland)* vol. 39,3 (2021): 294–300. doi:10.1159/000510950
- 66** Lönnermark, E., V. Friman, G. Lappas, T. Sandberg, A. Berggren, and I. Adlerberth. "Intake of Lactobacillus Plantarum Reduces Certain Gastrointestinal Symptoms During Treatment With Antibiotics." *Journal of Clinical Gastroenterology* 44.2 (2010): 106–12.
- 67** Klarin, B., M. Wulff, I. Palmquist, G. Molin, A. Larsson, and B. Jeppsson. "Lactobacillus Plantarum 299v Reduces Colonisation of Clostridium difficile in Critically Ill Patients Treated with Antibiotics." *Acta Anaesthesiologica Scandinavica* 52.8 (2008): 1096–102.
- 68** Niedzielin, K., H. Kordecki, and B. Birkenfeld. "A Controlled, Double-blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299v in Patients with Irritable Bowel Syndrome." *European Journal of Gastroenterology and Hepatology* 13.10 (2001): 1143–147.
- 69** Nobael, S., M. L. Johansson, G. Molin, S. Ahne, and B. Jeppsson. "Alteration of Intestinal Microflora Is Associated with Reduction in Abdominal Bloating and Pain in Patients with Irritable Bowel Syndrome." *The American Journal of Gastroenterology* 95.5 (2000): 1231–238.
- 70** Ducrotte, P., P. D. Sawant, and V. Jayanthi. "Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome." *World Journal of Gastroenterology* 18.30 (2012): 4012–018.
- 71** Kujawa-Szewieczek, A.; Adamczak, M.; Kwiecień, K.; Dudzic, S.; Gazda, M.; Więcek, A. "The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics." *Nutrients* 2015, 7, 10179–10188
- 72** A.C. Ouwehand et al. "Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study." *Vaccine* 32 (2014) 458–463
- 73** Engelbrektsson A, Korzenik JR, Pittler A, Sanders ME, Klaenhammer TR, Leyer G, Kitts CL. "Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy." *J Med Microbiol.* 2009 May;58(Pt 5):663–670. doi: 10.1099/jmm.0.47615-0 PMID: 19369530.
- 74** Steman L., Lehtinen M., Meland N., Christensen J.E., Yeung N., Saarinen M.T., Courtney M., Burcelin R., Lähedeo M., Linros J., Apter D., Scheinin M., Kloster Smerud H, Rissanen A., and Lahtiainen S.. "Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial." *EbioMedicina* 13 (2016): 190–200.
- 75** Ringel-Kulka T, Palsson OS, Maier D, et al. "Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders." *Journal of Clinical Gastroenterology.* 2011;45(6):518–525
- 76** Berggren, A., I.L. Åhrén, N. Larsson, and G. Önneng. "Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections." *European journal of nutrition* 50.3 (2011): 203–210.
- 77** Regina, B., G. Joerg, and D. Steffi. "Randomized, Double Blind and Placebo Controlled Study Using a Combination of Two Probiotic Lactobacilli to Alleviate Symptoms and Frequency of Common Cold." *Food and Nutrition Sciences* 2013 (2013).
- 78** Parkes, G. C., D. Chattoor, and A. Emmanuel. "The probiotic VSL# 3 increases scbm and reduces symptom severity scores in patients with functional constipation." *Gut* 60 Suppl 1 (2011): A163–A163
- 79** Sood, A., V. Midha, G.K. Makharla, V. Ahuja, D. Singal, P. Goswami, and R.K. Tandon. "The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis." *Clinical Gastroenterology and Hepatology* 7.1 (2009): 1202–1209.
- 80** Tursi, A., G. Brandimarte, G.M. Giorgetti, G. Forti, M.E. Modeo, and A. Gigliobianco. "Low-dose balsalazide plus a high-dose probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis." *Medical Science Monitor* 10.11 (2004): PI26–PI31.
- 81** Tursi, A., G. Brandimarte, A. Papa, A. Griglio, W. Elisei, G.M. Giorgetti, G. Forti, S. Morini, C. Hassan, M.A. Pistoia, and M.E. Modeo. "Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study." *The American Journal of Gastroenterology* 105.10 (2010): 2218–2227.
- 82** Gionchetti, P., F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, G. Poggiali, M. Miglioli, and M. Campieri. "Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial." *Gastroenterology* 19.2 (2000): 305–309.
- 83** Gionchetti, P., F. Rizzello, U. Helwig, A. Venturi, K. M. Lammers, P. Brigidi, B. Vitali, G. Poggiali, M. Miglioli, and M. Campieri. "Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial." *Gastroenterology* 124.5 (2003): 1202–1209.
- 84** Mimura, T., F. Rizzello, U. Helwig, G. Poggiali, S. Schreiber, I. C. Talbot, R. J. Nicholls, P. Gionchetti, M. Campieri, and M. A. Kamm. "Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis." *Gut* 53.1 (2004): 108–114.
- 85** Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open label randomized controlled trial of lactulose, probiotics and no therapy. *Am J Gastroenterol.* 2012;107:1043–1050.
- 86** Shukla S., Shukla A., Mehbood S., et al. "Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy." *Aliment Pharmacol Ther.* 2011;33:662–671.
- 87** Mittal, V.V. et al. "A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy." *European journal of Gastroenterology and Hepatology.* 2011, 23:725–732
- 88** Lunia, M.K. et al. "Probiotics Prevent Hepatic Encephalopathy in Patients With Cirrhosis: A Randomized Controlled Trial." *Clinical Gastroenterology and Hepatology.* 2014 Jun;12(6):1003–8
- 89** Kim SE, Choi SC, Park KS, Park MI, Shin JE, Lee TH, Jung KW, Koo HS, Myung SJ "Constipation Research group of Korean Society of Neurogastroenterology and Motility. Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation." *J Neurogastroenterol Motil.* 2015 Jan 1;21(1):111–20. doi: 10.5056/jnm14048. PMID: PMC4288088.
- 90** Duseja, Ajay et al. "High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study." *BMJ open gastroenterology* vol. 6,1:e000315. 7 Aug. 2019. doi:10.1136/bmgast/2019-000315
- 91** Román, Eva et al. "Effect of a Multistain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial." *Hepatology Communications* vol. 3,5:632–645. 12 Mar. 2019. doi:10.1002/hepc.41325
- 92** Indrio, F., G. Riezzo, F. Raimondi, M. Bisceglia, L. Cavallo, and R. Francavilla. "The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns." *The Journal of pediatrics* 152.6 (2008): 801–806.

- 93** Indrio, F., G. Riezzo, F. Raimondi, M. Bisceglia, A. Filannino, L. Cavallo, and R. Francavilla. "Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants." *European journal of clinical investigation* 41.4 (2011): 417-422.
- 94** Garofoli, F., E. Civardi, F. Indrio, I. Mazzucchelli, M. Angelini, C. Tinelli, and M. Stronati. "The early administration of Lactobacillus reuteri DSM 17938 controls regurgitation episodes in full-term breastfed infants." *International journal of food sciences and nutrition* 65.5 (2014): 646-648.
- 95** Savino, F., E. Pelle, E. Palumeri, R. Oggero, and R. Miniero. "Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study." *Pediatrics* 119.1 (2007): e124-e130.
- 96** Savino, F., L. Cordisco, V. Tarasco, E. Palumeri, R. Calabrese, R. Oggero, S. Roos, and D. Matteuzzi. "Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial." *Pediatrics* 126.3 (2010): e526-e533.
- 97** Sung, V., H. Hiscock, M.L.K. Tang, F.K. Mensah, M.L. Nation, C. Satzke, R.G. Heine, A. Stock, R.G. Barr, and M. Wake. "Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial." *BMJ* 348 (2014): q2107.
- 98** Chau, K., E. Lau, S. Greenberg, S. Jacobson, P. Yazdani-Brojeni, N. Verma, and G. Koren. "Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938." *The Journal of pediatrics* 166.1 (2015): 74-78.
- 99** Eom, T.H., E.Y. Oh, Y.H. Kim, H.S. Lee, P.S. Jang, D.U. Kim, J.T. Kim, and B.C. Lee. "The therapeutic effect of Lactobacillus reuteri in acute diarrhoea in infants and toddlers." *Korean Journal of Pediatrics* 48.9 (2005): 986-990.
- 100** Shorokhova, A.V., I.A. Kasas, E. Isolauri, H. Mykkänen, and T. Vesikari. "Lactobacillus reuteri as a therapeutic agent in acute diarrhoea in young children." *Journal of pediatric gastroenterology and nutrition* 24.4 (1997): 399-404.
- 101** Agustina, F.R., J.K. Kok, O. van de Rest, U. Fahimida, A. Firmansyah, W. Lukito, E.J.M. Feskens, E.H.G.M. van den Heuvel, R. Albers, and I.M.J. Bovee-Oudenhoven. "Randomized trial of probiotics and calcium on diarrhoea and respiratory tract infections in Indonesian children." *Pediatrics* 129.5 (2012): e1155-e1164.
- 102** Francavilla, R., E. Lionetti, S. Castellaneta, F. Cirizzi, F. Indrio, A. Masciale, C. Fontana, M. M. La Rosa, L. Cavallo, and A. Francavilla. "Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea-a double-blind study." *Alimentary pharmacology & therapeutics* 36.4 (2012): 363-369.
- 103** Dinleyici, E.C., and V. Yandepenlas. "Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children." *Acta Paediatrica* 103.7 (2014): e300-e305.
- 104** Lionetti, E., V. L. Minello, S. P. Castellaneta, A. M. Magista, A. De Canio, G. Maurogianni, E. Ierardi, L. Cavallo, and R. Francavilla. "Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial." *Alimentary pharmacology & therapeutics* 24.10 (2006): 1461-1468.
- 105** Cuccorillo, P., C. Strisciuglio, M. Martellini, E. Miele, L. Greco, and A. Stafano. "Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study." *The Journal of pediatrics* 157.4 (2010): 598-602.
- 106** Indrio, F., A. Di Mauro, G. Riezzo, E. Civardi, C. Intini, L. Corvaglia, E. Ballardini, M. Bisceglia, M. Cinquetti, E. Bazzaduro, and A. Del Vecchio. "Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial." *JAMA pediatrics* 168.3 (2014): 228-233.
- 107** Romano, C., F. Ferrau, F. Cavatorta, G. Iacono, M. Spina, E. Lionetti, F. Comisi, A. Famiani, and D. Comito. "Lactobacillus reuteri in children with functional abdominal pain (FAP)." *Journal of paediatrics and child health* 50.10 (2014): E68-E71.
- 108** Weizman, Z. "A Randomized Controlled Trial of Lactobacillus reuteri DSM 17938 in Functional abdominal pain of childhood." *SP-N-0102, Nutrition Trial symposia within the ESPGHAN program (9-12th of June, 2014 presented at 47th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, in Jerusalem).*
- 109** Weizman, Z., G. Asli, and A. Asheikh. "Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents." *Pediatrics* 115.1 (2005): 5-9.
- 110** Gutierrez-Castellon, P., G. Lopez-Velazquez, L. Diaz-Garcia, C. Jimenez-Gutierrez, J. Mancilla-Ramirez, J. Estevez-Jimenez, and M. Parra. "Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial." *Pediatrics* 133.4 (2014): e904-e909.
- 111** Abrahamsson, T.R., T. Jakobsson, M.F. Böttcher, M. Fredriksson, M.C. Jenmalm, B. Björkstén, and G. Oldaeus. "Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial." *Journal of Allergy and Clinical Immunology* 119.5 (2007): 1174-1180.
- 112** Forssberg et al. "Pre- and postnatal administration of Lactobacillus reuteri decreases TLR2 responses in infants" *Clinical and Translational Allergy* 2014; 4:21.
- 113** Mi GL, Zhao L et al. "Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial." *Antonie Van Leeuwenhoek*. 2015 Jun;107(6):1547-53.
- 114** Szajewska, Hania, et al. "Lactobacillus Reuteri DSM 17938 for the Management of Infantile Colic in Breastfed Infants: A Randomized, Double-Blind, Placebo-Controlled Trial." *The Journal of Pediatrics*, vol. 162, no. 2, Feb. 2013, pp. 257-262, doi:10.1016/j.jpeds.2012.08.004.
- 115** Hunter, C., M.V.T. Dimaguila, P. Gal, J.E. Wimmer, J.L. Ransom, R.Q. Carlos, M. Smith, and C.C. Davanzo. "Effect of routine probiotics Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight<1000 grams: a systematic analysis." *BMC pediatrics* 12.1 (2012): 1.
- 116** Athalye-Jape, Gayatri, et al. "Lactobacillus Reuteri DSM 17938 as a Probiotic for Preterm Neonates : A Strain-Specific Systematic Review." *Journal of Parenteral and Enteral Nutrition*, vol. 40, no. 6, Aug. 2016, pp. 783-794, doi:10.1177/10822173166558113.
- 117** Dimaguila M, Gal P, Wilson T, Wimmer Jr J, Smith Mc, Carlos R, Davanzo C, Ransom J. "Pharmacoeconomic impact of use of the probiotic Lactobacillus reuteri DSM 17938 for prevention of necrotizing enterocolitis in extremely low-birth-weight infants." *Research and Reports in Neonatology*, 2013;3:21-25 https://doi.org/10.2147/RRN.S43272
- 118** Szajewska, H., and J.Z. Mrukowicz. "Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials." *Journal of pediatric gastroenterology and nutrition* 33 (2001): S7-S25.
- 119** Basu, S., M. Chatterjee, S. Ganguly, and P.K. Chandra. "Efficacy of Lactobacillus rhamnosus GG in acute watery diarrhoea of Indian children: a randomised controlled trial." *Journal of paediatrics and child health* 43.12 (2007): 837-842.
- 120** Basu, S., D.K. Paul, S. Ganguly, M. Chatterjee, and P.K. Chandra. "Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial." *Journal of clinical gastroenterology* 43.3 (2009): 208-213.
- 121** Guardalini, S., L. Pensabene, M.A. Zikri, J.A. Dias, L.G. Casali, H. Hoekstra, S. Kolacek, K. Massar, D. Micetic-Turk, A. Papadopoulou, and J.S. de Sousa. "Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial." *Journal of pediatric gastroenterology and nutrition* 30.1 (2000): 54-60.
- 122** Ritchie, B.K., D.R. Brewster, C.D. Tran, G.P. Davidson, Y. McNiel, and R.N. Butler. "Efficacy of Lactobacillus GG in aboriginal children with acute diarrhoeal disease: a randomised clinical trial." *Journal of pediatric gastroenterology and nutrition* 50.6 (2010): 619-624.
- 123** Misra, S., T.K. Sabu, and N.K. Pal. "A randomized controlled trial to evaluate the efficacy of lactobacillus GG in infantile diarrhea." *The Journal of pediatrics* 155.1 (2009): 129-132.
- 124** Vanderhoof, J.A., D.B. Whitney, D.L. Antonson, T.L. Hanner, J.V. Lupo, and R.J. Young. "Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children." *The Journal of pediatrics* 135.5 (1999): 564-568.
- 125** Johnston, B.C., J.Z. Goldenberg, P.O. Vandvik, X. Sun, and G.H. Guyatt. "Probiotics for the prevention of pediatric antibiotic-associated diarrhea." *The Cochrane Library* (2011).
- 126** Gawrońska, A., P. Dzieciuchczar, A. Horvath, and H. Szajewska. "A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children." *Alimentary pharmacology & therapeutics* 25.2 (2007): 177-184.
- 127** Francavilla, R., V. Minello, A.M. Magistà, A. De Canio, N. Bucci, F. Gagliardi, E. Lionetti, S. Castellaneta, L. Polimeni, L. Peccarsi, and F. Indrio. "A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain." *Pediatrics* 126.6 (2010): e1445-e1452.
- 128** Hojsak, I., S. Abdoović, H. Szajewska, M. Milošević, Ž. Krznarić, and S. Kočaček. "Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections." *Pediatrics* 125.5 (2010): e1171-e1177.
- 129** Doege, K., D. Grajecki, B.C. Zryniak, E. Detinika, C. zu Eelenburg, and K.J. Buhling. "Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood—a meta-analysis." *British journal of nutrition* 107.01 (2012): 1-6.
- 130** Kalliomäki, M., S. Salminen, H. Arvilommi, P. Kero, P. Koskinen, and E. Isolauri. "Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial." *The Lancet* 357:926 (2001): 1076-1079.
- 131** Rautava, S., M. Kalliomäki, and E. Isolauri. "Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant." *Journal of Allergy and Clinical Immunology* 109.1 (2002): 119-121.
- 132** Kalliomäki, M., S. Salminen, T. Poussa, H. Arvilommi, and E. Isolauri. "Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial." *The Lancet* 363:9372 (2003): 1869-1871.
- 133** Kalliomäki, M., S. Salminen, T. Poussa, and E. Isolauri. "Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial." *Journal of Allergy and Clinical Immunology* 119.4 (2007): 1019-1021.
- 134** Dotterud, C. K., O. Storrø, R. Johnsen, and T. Øien. "Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial." *British Journal of Dermatology* 163.3 (2010): 616-623.
- 135** Boyle, R. J., I. H. ISMAIL, S. KIVIUVONEN, P. LIKICCIARDI, R. M. ROBBINS-BROWNE, L-J. MAH, C. AXELRAD, S. MOORE, S. DONATH, J.B. CARLIN, and S.J. LAHTINEN. "Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial." *Allergy* 66.4 (2011): 509-516.
- 136** Lavekar, A.S., D.V. Raje, T. Manohar, and A.A. Lavekar. "Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis." *Eurasian J Hepat-Gastroenterol* 7.2 (2017): 130-37.
- 137** Vairo, P., C. Mandato, M.R. Licenziati, A. Franzese, D.F. Vitale, S. Lenta, M. Caropreso, G. Vallone, and R. Meli. "Effects of Lactobacillus Rhamnosus Strain GG in Pediatric Obesity-related Liver Disease." *Journal of Pediatric Gastroenterology and Nutrition* 52.6 (2011): 740-43.
- 138** Szajewska, H., Kolodziejczak, M., et al. "Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children - a 2019 Update." *Aliment Pharmacol Ther*. 2019;00:1-9.
- 139** Hojsak I, Novak N et al. "Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: A randomized, double-blind, placebo-controlled trial" *Clinical Nutrition* 29 (2010) 312-316
- 140** Carucci, Laura et al. "Therapeutic effects elicited by the probiotic Lactisicebacillus rhamnosus GG in children with atop dermatitis. The results of the ProPAd trial." *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* vol. 33.8 (2022): e13836. doi:10.1111/pai.13836
- 141** Chen, Ke et al. "Infantile Colic Treated With Bifidobacterium longum CECT7894 and Pediacoccus pentosaceus CECTB330: A Randomized, Double-Blind, Placebo-Controlled Trial." *Frontiers in pediatrics* vol. 9 (2020) 635176.
- 142** Moreno-Villares, J. M et al. "Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediacoccus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM7938 in the management of infant colic: a randomized clinical trial." *European journal of pediatrics* vol. 183,12 (2024): 5371-5381

- 143** Htwe, K., K.S. Yee, M. Tin, and Y. Vandenberg. "Effect of *Saccharomyces boulardii* in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study." *The American journal of tropical medicine and hygiene* 78.2 (2008): 214-216.
- 144** Kurugöl, Z., and G. Koturoğlu. "Effects of *Saccharomyces boulardii* in children with acute diarrhoea." *Acta Paediatrica* 94.1 (2005): 44-47.
- 145** Feizizadeh, S., A. Salehi-Abargouei, and V. Akbari. "Efficacy and safety of *Saccharomyces boulardii* for acute diarrhea." *Pediatrics* (2014): ped-2013.
- 146** Kotowska, M., P. Albrecht, and H. Szajewska. "Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial." *Alimentary pharmacology & therapeutics* 21.5 (2005): 583-590.
- 147** Buts, J.P., G. Corthier, and M. Delmege. "Saccharomyces boulardii for *Clostridium difficile*-associated enteropathies in infants." *Journal of medical gastroenterology and nutrition* 16.4 (1993): 419-425.
- 148** Bin, Zhang, et al. "The efficacy of Saccharomyces boulardii CNCM 1-745 in addition to standard Helicobacter pylori eradication treatment in children." *Pediatric gastroenterology, hepatology and nutrition* 18.1 (2015): 17-22.
- 149** Garaiova, I., J. Muchová, Z. Nagyová, Duolao Wang, J. V. Li, Z. Országová, D. R. Michael, S. F. Plummer, and Z. Durácková. "Probiotics and vitamin C for the prevention of respiratory tract infections in children attending preschool: a randomised controlled pilot study." *European journal of clinical nutrition* 69.3 (2015): 373-379.
- 150** Rautava, S., S. Salminen, and E. Isolauri. "Specific probiotics in reducing the risk of acute infections in infancy—a randomised, double-blind, placebo-controlled study." *British Journal of Nutrition* 101.11 (2009): 1722-1726.
- 151** Schmidt RM, Pilmann Laursen R, Bruun S, et al. "Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial." *Pediatr Allergy Immunol*. 2019;00:1-6.
- 152** Leyfer, G.J., S. Li, M.E. Mubasher, C. Reifer, and A.C. Ouwehand. "Probiotic effects on cold and influenza-like symptom incidence and duration in children." *Pediatrics* 124.2 (2009): e172-e179.
- 153** Alamoudi, Najlaa M et al.: "Effect of Probiotic Lactobacillus reuteri on Salivary Cariogenic Bacterial Counts among Groups of Preschool Children in Jeddah, Saudi Arabia: A Randomized Clinical Trial." *The Journal of clinical pediatric dentistry* vol. 42,5 (2018): 331-338. doi:10.17796/1053-4625.42-5
- 154** Cannon, Mark E. et al.: "Effectiveness of CRT at measuring the salivary level of bacteria in caries prone children with probiotic therapy." *The Journal of clinical pediatric dentistry* vol. 36,1 (2013): 55-60. doi:10.1796/jcpd.38.1.6481624264142082
- 155** Maya-Barrios, A et al.: "Limosilactobacillus reuteri ATCC PTA 5289 and DSM 17938 as adjuvants to improve evolution of pharyngitis/tonsillitis in children: randomised controlled trial." *Beneficial microbes* vol. 12,2 (2021): 137-145. doi:10.3920/BM2020.071
- 156** Navarro-López, Vicente et al. "Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial." *JAMA dermatology* vol. 154.1 (2018): 37-43.
- 157** Tan-Lim, Carol Stephanie C et al. "Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: A systematic review and network meta-analysis." *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*, 10.1111/pai.13305. 10 Jun. 2020, doi:10.1111/pai.13305
- 158** Taipale, T., K. Pienihäkkinen, E. Isolauri, C. Larsen, E. Brockmann, P. Alelanen, J. Jokela, and E. Söderling. "Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy." *British Journal of Nutrition* 105.3 (2011): 409-416.
- 159** Nocerino et al. "The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: A randomised, double blind, placebo-controlled trial." *Aliment Pharmacol Ther*. 2019;00:1-11.
- 160** Dubey, A.P., R. Krishnan, A. Chakravarti, A. Aggarwal, B.K. Atal, C. De Simone, V. Pandey, and A.R. Sahu. "W1772 Use of VSL#3 (a New High Concentration Probiotic Mixture) in the Treatment of Childhood Diarrhea with Specific Reference to Rotavirus Diarrhea." *Gastroenterology* 134.4 (2008): A-712.
- 161** Huynh, H.Q., J. deBruyn, L. Guan, H. Diaz, M. Li, S. Girgis, J. Turner, R. Fedorak, and K. Madsen. "Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study." *Inflammatory bowel diseases* 15.5 (2009): 760-768.
- 162** Miele, E., F. Pasarelli, E. Giannetti, L. Quaglia, R.N. Baldassano, and A. Staiano. "Effect of a Probiotic Preparation (VSL#3) on induction and maintenance of Remission in children with ulcerative colitis." *The American journal of gastroenterology* 104.2 (2009): 437-443.
- 163** Guardalini, S., G. Magazza, A. Chiaro, V. La Balestra, G. Di Nardo, S. Gopalan, A. Sibal, C. Romano, R.B. Canani, P. Lionetti, and M. Setty. "VSL #3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study." *Journal of pediatric gastroenterology and nutrition* 51.1 (2010): 24-30.
- 164** Alisi, A., G. Bedogni, G. Baviera, V. Giorgio, E. Porro, C. Paris, P. Giannaria, L. Reali, F. Anania, and V. Nobili. "Randomised Clinical Trial: The Beneficial Effects of VSL#3 in Obese Children with Non-alcoholic Steatohepatitis." *Alimentary Pharmacology & Therapeutics* 39.11 (2014): 1276-285.
- 165** Anukam, K., E. Osazuwa, I. Ahonkhai, M. Ngwu, G. Osemene, A.W. Bruce, and G. Reid. "Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial." *Microbes and Infection* 8.6 (2006): 1450-1454.
- 166** Reid, G., D. Charbonneau, J. Erb, B. Kochanowski, D. Beumeran, R. Poehler, and A.W. Bruce. "Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alter vaginal flora: a randomized, placebo-controlled trial in 6 healthy women." *FEMS Immunology & Medical Microbiology* 35.2 (2003): 131-134.
- 167** Anukam, K.C., E. Osazuwa, G.I. Osemene, F. Ehigbare, A.W. Bruce, and G. Reid. "Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis." *Microbes and Infection* 8.12 (2006): 2772-2776.
- 168** Hummelen, R., J. Changalucha, N.L. Butamanya, A. Cook, J.D.F. Habberma, and G. Reid. "Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV." *International Journal of Gynecology & Obstetrics* 113 (2010): 245-248.
- 169** Reid, G., A.W. Bruce, N. Fraser, C. Heinemann, J. Owen, and B. Henning. "Oral probiotics can resolve urogenital infections." *FEMS Immunology & Medical Microbiology* 30.1 (2001): 49-52.
- 170** Martinez, R.C., S.A. Franceschini, M.C. Patta, S.M. Quintana, R. C. Candido, J. C. Ferreira, E. C. P. De Martinis, and G. Reid. "Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14." *Letters in applied microbiology* 48.3 (2009): 269-274.
- 171** Martinez, R.C., S.A. Franceschini, M.C. Patta, S.M. Quintana, B.C. Gomes, E.C. De Martinis, and G. Reid. "Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial." *Canadian journal of microbiology* 55.2 (2009): 133-138.
- 172** Vujic, G., A.J. Knez, D.B. Stefanovic, and V.K. Vrbancic. "Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study." *European Journal of Obstetrics & Gynecology and Reproductive Biology* 168.1 (2013): 75-79.
- 173** Ya, W., C. Reifer, and L.E. Miller. "Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study." *American journal of obstetrics and gynecology* 203.2 (2010): 120-e1.
- 174** Kern, A., M. J. M. Bobot, and J. M. Cardot. "Preventive treatment of vulvovaginal candidosis with vaginal probiotic (gynophilus®-lcr regenerans®): Results of the observational study candiflore." *La Lettre du Gynécologue* 370 (2012): 33-7.
- 175** Marcone, V., G. Rocca, M. Lichtner, and E. Calzolari. "Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis." *International Journal of Gynecology & Obstetrics* 110.3 (2010): 223-226.
- 176** Petriccive, L., and A. Witt. "The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis." *BJOG: An International Journal of Obstetrics & Gynaecology* 115.11 (2008): 1369-1374.
- 177** Rossi, A., T. Rossi, M. Bertini, and G. Caccia. "The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. Evaluation of clinical efficacy in a population of 40 women treated for 24 months." *Archives of gynecology and obstetrics* 281.6 (2010): 1065-1069.
- 178** Agrawal, A., Lesley A. Houghton, J. Morris, B. Reilly, D. Guyonnet, N. Goupil Feuillerat, A. Schlumberger, S. Jakob, and P. J. Whorwell. "Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation." *Alimentary pharmacology & therapeutics* 29.1 (2009): 104-114.
- 179** Guyonnet, D., O. Chassany, P. Durocute, C. Picard, M. Mouret, C.-H. Mercier, and C. Matuchansky. "Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial." *Alimentary pharmacology & therapeutics* 26.3 (2007): 475-486.
- 180** Yang, Y.X., M. He, G. Hu, J. Wei, P. Pages, X.H. Yang, and S. Bourdu-Naturel. "Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women." *World J Gastroenterol* 14.40 (2008): 6237-6243.
- 181** Saavedra, J.M., A. Abi-Hanna, N. Moore, and R.H. Yolken. "Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety." *The American journal of clinical nutrition* 79.2 (2004): 261-267.
- 182** Corrêa, N.B., L.A. Pérêt Filho, F.J. Penna, F.M.S. Lima, and J.R. Nicolí. "A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants." *Journal of clinical gastroenterology* 39.5 (2005): 385-389.
- 183** Baldassarre M.E., Laforgia N., Fanelli M., Laneve A., Grossi R., and Lifschitz C. "Lactobacillus GG Improves Recovery in Infants with Blood in the Stools and Presumptive Allergic Colitis Compared with Extensively Hydrolyzed Formula Alone." *The Journal of Pediatrics* 156.3 (2010): 397-401.
- 184** Canani, R.B., Nocerino R., Terrin G., Frediani T., Lucarelli S., Cosenza L., Passariello A., Leone L., Granata V., Di Costanzo M., Pezzella V., and Troncone R. "Formulation Search for Management of Children with Cow's Milk Allergy Influences the Rate of Acquisition of Tolerance: A Prospective Multicenter Study." *The Journal of Pediatrics* 163.3 (2013)
- 185** Canani, R.B., Di Costanzo M., Bedogni G., Amoruso A., Cosenza L., Di Scalzi C., Granata V., and Nocerino R. "Extensively Hydrolyzed Casein Formula Containing Lactobacillus rhamnosus GG Reduces the Occurrence of Other Allergic Manifestations in Children with Cow's Milk Allergy: 3-year Randomized Controlled Trial." *Journal of Allergy and Clinical Immunology* 139.6 (2017)
- 186** Nocerino, Rita et al.: "The Impact of Formula Choice for the Management of Pediatric Cow's Milk Allergy on the Occurrence of Other Allergic Manifestations: The Atopic March Cohort Study." *The Journal of pediatrics* vol. 232 (2021): 183-191.e3. doi:10.1016/j.jpeds.2021.01.059
- 187** Koebnick, C., Wagner, I., Leitzmann, P., Stern, U., and Zunft, H. (2003). Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. *Can J Gastroenterol* 17, 655-659.

- 188** Tilley, L., Keppens, K., Kushiro, A., Takada, T., Sakai, T., Vaneechoutte, M., and Degeest, B. (2014). A probiotic fermented milk drink containing *Lactobacillus casei* strain Shirata improves stool consistency of subjects with hard stools. *International Journal Of Probiotics And Prebiotics* 9, 23-30.
- 189** Dong, H., Rowland, I., Thomas, L., and Yaqoob, P. (2013). Immunomodulatory effects of a probiotic drink containing *Lactobacillus casei* Shirata in healthy older volunteers. *European Journal Of Nutrition* 52, 1853-1863.
- 190** Gleeson, M., Bishop, N., Oliveira, M., and Tauler, P. (2011). Daily probiotic's (*Lactobacillus casei* Shirata) reduction of infection incidence in athletes. *International Journal Of Sport Nutrition And Exercise Metabolism* 21, 55-64.
- 191** Ivory, K., Chambers, S., Pin, C., Prieto, E., Arqués, J., and Nicoletti, C. (2008). Oral delivery of *Lactobacillus casei* Shirata modifies allergen-induced immune responses in allergic rhinitis. *Clinical & Experimental Allergy* 38, 1282-1289.
- 192** Nagao, F., Nakayama, M., Muto, T., and Okumura, K. (2000). Effects of a Fermented Milk Drink Containing *Lactobacillus casei* Strain Shirata on the Immune System in Healthy Human Subjects. *Bioscience, Biotechnology And Biochemistry* 64, 2706-2708.
- 193** Rao A.V., Bested A.C., Beaulne T.M., Katzman M.A., Iorio C., Berardi J.M., and Logan A.C. "A Randomized, Double-blind, Placebo-controlled Pilot Study of a Probiotic in Emotional Symptoms of Chronic Fatigue Syndrome." *Gut Pathogens* 1 (2009): 6.
- 194** Kato-Kataoka A., Nishida K., Takada M., Suda K., Kawai M., Shimizu K., Kushiro A., Hoshi R., Watanabe O., Igarashi T., Miyazaki K., Kuwano Y., and Rokutan K. "Fermented Milk Containing *Lactobacillus Casei* Strain Shirata Prevents the Onset of Physical Symptoms in Medical Students under Academic Examination Stress." *Beneficial Microbes* 7.2 (2016): 153-56.

This Clinical Guide is available online at www.ProbioticChart.ca

For inquiries related to the content, please contact author Dragana Skokovic-Sunjic DSunjic@bhsoftinc.com

For ordering additional copies of this Clinical Guide, contact info@bhsoftinc.com



The Clinical Guide to Probiotic Products Available in Canada is made possible through an unrestricted education grant from the Alliance for Education on Probiotics (AEProbio).

Product inclusion in The Clinical Guide to Probiotic Products Available in Canada is based on scientific evidence and is not influenced by or limited to members of AEProbio.

Alliance Members Canada



Alliance Members USA





AEProbio

Alliance for Education on Probiotics

Your trusted resource for selecting probiotics.

AEProbio (the Alliance for Education on Probiotics) is dedicated to establishing probiotics as front-line therapy for the protection, restoration and enhancement of human health. Every year, we provide an unbiased review and summary of the available scientific evidence on the efficacy of specific probiotic products.

www.AEProbio.com

Visit the Probiotic Guide Website:



Get the Probiotic Guide App:

